Pharmacology Research & Perspectives
May 10, 2026
Jessie Kim, Liam Lochhead, Cory R. Weissman
Interest in psychedelic-assisted therapy (PAT) is surging across research and medical communities, prompting the discussion of policy shifts that reflect growing openness to implementing psychedelics in clinical practice. State-level psychedelic reform in the United States has accelerated since 2019, with legalization projected to reach most states within the next decade if trends follow those...
Pharmacology Research & Perspectives
April 1, 2026
Jordana Kazdan, Karim S Ladha, Muhammad Ishrat Husain
Major Depressive Disorder (MDD) and chronic pain are independently debilitating conditions that frequently co-occur. This comorbidity poses a significant clinical challenge, resulting in greater symptom severity, higher disability, and worse prognosis than either condition alone. Current therapies often address each disorder in isolation, leaving individuals with comorbid MDD and chronic pain...
Pharmacology Research & Perspectives
April 1, 2025
Eduardo Ekman Schenberg
9 citations
ABSTRACT The recent review of a new drug application for MDMA‐assisted therapy for posttraumatic stress disorder by the United States' Food and Drug Administration (FDA) highlighted epistemological and methodological challenges for evidence assessments. Similar challenges will also be faced in reviews of other compounds in early‐ and late‐stage development, like psilocybin for depression. The...
Pharmacology Research & Perspectives
February 25, 2025
Mohammad Balabandian, Mohammad Amin Manavi, Ali Lesani et al.
4 citations
ABSTRACT Epilepsy, a chronic neurological disorder affecting around 65 million people globally, is characterized by recurrent, unprovoked epileptic seizures. Psilocin, the active metabolite of psilocybin, a well‐known psychedelic compound, has recently gained attention for its potential antidepressant and anxiolytic properties. This study aims to investigate the anticonvulsant effects of...
Pharmacology Research & Perspectives
August 1, 2024
Ari Brouwer, Robin Carhart-Harris, Charles L. Raison
5 citations
It is a paradox that psychotomimetic drugs can relieve symptoms that increase risk of and cooccur with psychosis, such as attention and motivational deficits (e.g., amphetamines), pain (e.g., cannabis) and symptoms of depression (e.g., psychedelics, dissociatives). We introduce the ideas of psychotomimetic compensation and psychotomimetic sensitization to explain this paradox. Psychotomimetic...
Pharmacology Research & Perspectives
February 2, 2021
Benjamin Stewart, Jon G Dean, Adriana Koek et al.
15 citations
Abstract Functional neurological disorders (FNDs), which are sometimes also referred to as psychogenic neurological disorders or conversion disorder, are common disabling neuropsychiatric disorders with limited treatment options. FNDs can present with sensory and/or motor symptoms, and, though they may mimic other neurological conditions, they are thought to occur via mechanisms other than...